https://www.selleckchem.com/pr....oducts/plerixafor.ht
ositive prognostic markers, while HIF-1α is a negative prognostic marker of breast cancer. Conclusions Our study identifies TFEB as a master regulator of TAMs in breast cancer. TFEB controls TAM gene expression and function through multiple autophagy/lysosome-dependent and independent pathways. Therefore, pharmacological activation of TFEB would be a promising therapeutic approach to improve the efficacy of existing treatment including immune therapies for breast cancer by favorably modulating TAM function and the TME.Background The
Like
Comment
Share
